Clinical Trial Update: Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Results from a Phase 1/2 clinical trial of the radiolabeled imaging agent 89Zr-DFO-MSTP2109A in prostate cancer have been posted; the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 89Zr-DFO-MSTP2109A

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-10-02